화학공학소재연구정보센터
홈 로그인 로그아웃 연락처 사이트맵
Journal of Industrial and Engineering Chemistry, Vol.110, 456-470, June, 2022
DOI10.1016/j.jiec.2022.03.022  Export Citation
Efficient starvation therapy with three-pathway blocking in combination with PTT/CDT for TME reversal and tumor apoptosis
Mengchao Ding, Xiaoying Kong, Weiyan Chen, Lei Yan1, He Huang1, Zunzhou Lv1, Peng Jiang2, Ali Mu2, Congcong Huang3, and Jinsheng Shi†
  • College of Chemistry and Pharmaceutical Sciences, Qingdao Agricultural University, Qingdao 266109, China
  • 1Shandong New Hope Liuhe Group Co., Ltd., Qingdao 266000, China
  • 2Qingdao Agricultural Products Quality and Safety Center, Qingdao 266000, China
  • 3Qingdao Jimo Animal Disease Control Center, Qingdao 266200, China
E-mail:
Single cancer starvation therapy (ST) strategy can’t achieve satisfactory anti-tumor effect, mainly due to the diversified nutritional sources of tumor cells. Herein, CuS@Axitinib-SiO2@2-Deoxy-D-glucose(2-DG)- CaCO3-RGD nanoparticles (CADCR NPs) were prepared for three-pathway blocking for efficient starvation therapy as well as reinforced photothermal therapy (PTT) and chemodynamic therapy (CDT). After CADCR NPs were targeted to tumor cells, CaCO3 was ruptured in the acidic environment, releasing Ca2+ to chelate glutamine and cutting off the glutamine metabolic pathway of the tumor. 2-DG was also released from mesoporous SiO2 and restrained the glycolytic pathway of tumor cells. In addition, under the thermal stimulus of near-infrared irradiation, axitinib was released from CuS NPs, which inhibited the proliferation of tumor blood vessels, ultimately inhibiting the aerobic respiratory pathway of tumor cells. Interestingly, CADCR NPs also showed potential to reshape the tumor microenvironment (TME) and promoted the transformation of macrophages from M2 to M1 type, increasing the expression of CD8+ T cells in the tumor site. In conclusion, CADCR NPs achieve severe tumor starvation by simultaneously interfering with three energy metabolic pathways, and further enhance tumor treatment with the aid of PTT, CDT, and TME improvement, which exhibits great potential for clinical cancer therapy.
Keywords:Three-pathway blocking;Starvation therapy;Photothermal therapy/chemodynamic;therapy;CADCR nanoparticle;Acitivated immunotherapy
  1. Shao F, Wu Y, Tian Z, Liu S, Biomaterials, 274, 120869 (2021)
  2. Fu LH, Qi C, Hu YR, Lin J, Huang P, Adv. Mater., 31, 1808325 (2019)
  3. Zhang M, Ye JJ, Xia Y, Wang ZY, Li CX, Wang XS, et al., ACS Nano, 13, 14230 (2019)
  4. De Palma M, Biziato D, Petrova TV, Nat. Rev. Cancer, 17, 457 (2017)
  5. Zhang C, Ni D, Liu Y, Yao H, Bu W, Shi J, Nat. Nanotechnol., 12, 378 (2017)
  6. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK, Nat. Rev. Clin. Oncol, 15, 325 (2018)
  7. Kanugula AK, Adapala RK, Jamaiyar A, Lenkey N, Guarino BD, Liedtke W et al., Angiogenesis, 24, 647 (2021)
  8. Taleb M, Ding Y, Wang B, Yang N, Han X, Du C, et al., Adv. Healthc. Mater., 8, 1900283 (2019)
  9. Zhou Y, Ren X, Hou Z, Wang N, Jiang Y, Luan Y, Nanoscale Horiz., 6, 120 (2021)
  10. Li X, Li Y, Lu W, Chen M, Ye W, Zhang D, Cells, 8, 1602 (2019)
  11. Lv Y, Zhao X, Zhu L, Li S, Xiao Q, He W, et al., Theranostics, 8, 2830 (2018)
  12. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al., Nature, 496, 101 (2013)
  13. Li X, Wenes M, Romero P, Huang SCC, Fendt SM, Ho PC, Nat. Rev. Clin. Oncol., 16, 425 (2019)
  14. Sukumar M, Roychoudhuri R, Restifo NP, Cell, 162, 1206 (2015)
  15. Cenigaonandia-Campillo A, Serna-Blasco R, Gómez-Ocabo L, Solanes-Casado S, Baños-Herraiz N, Puerto-Nevado LD, et al., Theranostics, 11, 3595 (2021)
  16. Li W, Liu S, Dong S, Gai S, Zhang F, Dong Y, et al., Chem. Eng. J., 405, 127027 (2021)
  17. Cai Z, Li CF, Han F, Liu C, Zhang Z, Hsu CC, et al., Mol. Cell., 80, 263 (2020)
  18. Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, et al., J. Clin. Invest., 130, 3865 (2020)
  19. Brown TP, Ganapathy V, Pharmacol. Ther., 206, 107451 (2020)
  20. Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y, et al., Nat. Commun., 11, 1320 (2020)
  21. Zubair H, Azim S, Srivastava SK, Ahmad A, Bhardwaj A, Khan MA, et al., Cancer Res., 76, 7254 (2016)
  22. Chen C, Bai L, Cao F, Wang S, He H, Song M, et al., Oncogene, 38, 4527 (2019)
  23. Lee P, Malik D, Perkons N, Huangyang P, Khare S, Rhoades S, et al., Nat. Commun., 11, 498 (2020)
  24. Guo Y, Jia HR, Zhang X, Zhang X, Sun Q, Wang SZ, et al., Small, 16, 2000897 (2020)
  25. Yang C, Younis MR, Zhang J, Qu J, Lin J, Huang P, Small, 16, 2001518 (2020)
  26. Chen L, Zhou L, Wang C, Han Y, Lu Y, Liu J, et al., Adv. Mater., 31, 1904997 (2019)
  27. Yu Y, Song M, Chen C, Du Y, Li C, Han Y, et al., ACS Nano, 14, 10688 (2020)
  28. Zhang M, Qin X, Xu W, Wang Y, Song Y, Garg S, et al., J. Colloid Interface Sci., 594, 493 (2021)
  29. Li QL, Sun Y, Ren L, Wang X, Wang C, Li L, et al., Mater. Interfaces, 10, 29314 (2018)
  30. Chang M, Wang M, Wang M, Shu M, Ding B, Li C, et al., Adv. Mater., 31, 1905271 (2019)
  31. Dou WT, Xu F, Xu CX, Gao J, Ru HB, Luan X, et al., Chem. Sci., 12, 11089 (2021)
  32. Goldberg L, Israeli R, Kloog Y, Cell Death Dis., 3, e284 (2012)
  33. Van der Veken B, De Meyer GRY, Martinet W, Vasc. Pharmacol., 100, 34 (2018)
  34. Zhu H, Wang J, Wu D, Inorg. Chem., 48, 7099 (2009)
  35. Hu XY, Gao L, Mosel S, Ehlers M, Zellermann E, Jiang H, et al., Small, 14, e1803952 (2018)
  36. Tang S, Meng Q, Sun H, Su J, Yin Q, Zhang Z, et al., Biomaterials, 114, 44 (2017)
  37. Liu F, Lin L, Zhang Y, Wang Y, Sheng S, Xu C, et al., Adv. Mater., 31, e1902885 (2019)
  38. Yu F, Tu Y, Luo S, Xiao X, Yao W, Jiang M, et al., Nano Lett., 21, 2216 (2021)
  39. Dong Y, Tu Y, Wang K, Xu C, Yuan Y, Wang J, Angew. Chem.-Int. Edit., 59, 7168 (2020)
  40. Xu C, Yan Y, Tan J, Yang D, Jia X, Wang L, et al., Adv. Funct. Mater., 29, 1808146 (2019)
  41. Gao F, Tang Y, Liu WL, Zou MZ, Huang C, Liu CJ, et al., Adv. Mater., 31, 1904639 (2019)
  42. de la Cruz López KG, Castro Muñoz LJ, Reyes Hernández DO, García Carrancá A, Manzo Merino J, Front. Oncol., 9, 1143 (2019)
  43. Petovári G, Dankó T, Tokés AM, Vetlényi E, Krencz I, Raffay R, et al., Cancers, 12, 2492 (2020)
  44. Jiao L, Zhang HL, Li DD, Yang KL, Tang J, Li X, et al., Autophagy, 14, 671 (2018)
  45. Ji TJ, Feng B, Shen J, Zhang M, Hu YQ, Jiang AX, et al., Adv. Sci., 8, e2100351 (2021)
  46. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al., Clin. Cancer Res., 14, 7272 (2008)
  47. Choi JY, Ramasamy T, Kim SY, Kim J, Ku SK, Youn YS, et al., Acta Biomater., 39, 94 (2016)
  48. Allen E, Miéville P, Warren CM, Saghafinia S, Li L, Peng MW, et al., Cell Rep., 15, 1144 (2016)
  49. Wang XS, Zeng JY, Zhang MK, Zeng X, Zhang XZ, Adv. Funct. Mater., 28, 1801783 (2018)
  50. Zhang A, Xu Y, Xu H, Ren J, Meng T, Ni Y, et al., Theranostics, 11, 3839 (2021)
  51. Colegio OR, Oncoimmunology, 5, e1014774 (2016)
  52. Wang R, Lu M, Chen H, Chen S, Luo X, Qin Y, Zhang J, J. Exp. Clin. Canc. Res., 30, 62 (2011)
  53. Beyranvand Nejad E, Labrie C, van Elsas MJ, Kleinovink JW, Mittrucker HW, Franken K, et al., Cancer, 9, e002460 (2021)
  54. Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo X, et al., Nano Lett., 21, 4231 (2021)